	US 12,239,696 B2
	Chimeric vaccine antigens for anaplasmosis
Richard T. Marconi, Midlothian, VA (US); and Jason A. Carlyon, Richmond, VA (US)
Assigned to Virginia Commonwealth University, Richmond, VA (US)
Filed by VIRGINIA COMMONWEALTH UNIVERSITY, Richmond, VA (US)
Filed on Feb. 1, 2022, as Appl. No. 17/590,290.
Application 17/590,290 is a continuation of application No. 17/048,296, granted, now 11,273,213, previously published as PCT/US2019/027895, filed on Apr. 17, 2019.
Claims priority of provisional application 62/658,709, filed on Apr. 17, 2018.
Prior Publication US 2022/0152180 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/02 (2006.01); A61P 31/04 (2006.01); A61P 37/04 (2006.01); C07K 14/195 (2006.01)

CPC A61K 39/0233 (2013.01) [A61P 31/04 (2018.01); A61P 37/04 (2018.01); C07K 14/195 (2013.01)]

2 Claims

1. A method of eliciting an immune response to Anaplasma

in a subject in need thereof, comprising

administering to the subject an amount of a pharmaceutical composition comprising a recombinant, chimeric polypeptide, wherein the amino acid sequence of the recombinant, chimeric polypeptide is selected from the group consisting of:

SEQ ID NO: 8;

SEQ ID NO: 9;

SEQ ID NO: 10;

SEQ ID NO: 11;

SEQ ID NO: 12;

SEQ ID NO: 13;

SEQ ID NO: 14;

SEQ ID NO: 15;

SEQ ID NO: 16;

SEQ ID NO: 17;

SEQ ID NO: 18;

SEQ ID NO: 19;

SEQ ID NO: 20;

SEQ ID NO: 21;

SEQ ID NO: 22;

and

SEQ ID NO: 23, wherein the amount is sufficient to elicit an immune response in the subject.